Andrx Announces Approval of Metformin HCl Extended-Release Tablets, 75

    Pharmaceutical Writers/Business Editors/Health Editors

    FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--April 13, 2005--Andrx Corporation (Nasdaq:ADRX) today announced that the United States Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for metformin hydrochloride extended-release tablets, 750mg. Andrx has already commenced shipping this product.
    Andrx's metformin HCl ER tablets, 750mg, are the AB-rated generic equivalent of Bristol-Myers Squibb's Glucophage(R) XR Tablets, 750mg, a product indicated for the treatment of type 2 diabetes.

    About Andrx Corporation

    We are a pharmaceutical company that develops, manufactures and commercializes generic versions of controlled-release, niche and immediate-release pharmaceutical products, including oral contraceptives. We also distribute pharmaceuticals, primarily generics, which have been commercialized by others, as well as our own, primarily to independent pharmacies, pharmacy chains, pharmacy buying groups and physicians' offices.
    Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of Andrx that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the commercial success of Andrx's generic metformin hydrochloride extended-release tablets, 750mg product, Andrx's dependence on a relatively small number of products, licensing revenues, the timing and outcome of litigation and future product launches, government regulation, competition, and manufacturing capacities, safety issues, output and quality processes. Andrx Corporation is also subject to other risks detailed herein or detailed from time to time in its filings with the U.S. Securities and Exchange Commission. Andrx disclaims any responsibility to update the statements contained herein.
    This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com.

--30--JAR/mi*

CONTACT: Andrx Corporation, Fort Lauderdale Allison Tomek, 954-382-7696 Email: Allison.tomek@andrx.com

KEYWORD: FLORIDA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL PRODUCT SOURCE: Andrx Corporation

Copyright Business Wire 2005